Maxim Group Maintains Bullish View on BioLineRx (BLRX) Amid Follow-Up Data for BL-8040
Tweet Send to a Friend
Maxim Group analyst Jason McCarthy reiterated a Buy rating and $2 price target on BioLineRx (NASDAQ: BLRX) after the company ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
